RxDoctor Payments Data

Phillip Mackinder

Optometrist · Deland, FLNPI 1730171174

Payments from drug & device makers

$2,936in general payments, 2019–2025

Across 84 payments — averaging $34.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • Bausch & Lomb Americas Inc.$367
  • Amgen$205
  • Johnson & Johnson Vision Care, Inc.$199
  • Harrow Eye, LLC$174
  • Glaukos Corporation$167
  • plus $752 from 12 others

What the payments were for

  • Food & beverage$2,936100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,936 in reported general payments places this provider in the 75th percentile of 3,166 optometrist providers in Florida.

See all optometrist providers in Florida

Medicare billing

Part B allowed, 2024
$212,639
Medicare patients
1,099
Services billed
2,422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine21$16,961
XiidraLifitegrast11$16,150
LumiganBimatoprost32$15,178
Travoprost58$9,428
Alphagan PBrimonidine Tartrate14$7,166
Latanoprost347$6,174
RocklatanNetarsudil Mesylat/Latanoprost17$5,598
Cyclosporine11$4,614
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat80$1,773
Timolol Maleate81$1,603
Prednisolone Acetate26$825
Brimonidine Tartrate46$727
Dorzolamide Hcl23$423
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha17$204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P$104$39,30667 claims
Bausch & Lomb Americas Inc.Xiidra$367$16,15011 claims
Aerie Pharmaceuticals, Inc.Rocklatan$15$5,59817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,166 optometrist providers in Florida.

Other optometrist in Deland

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →